IP lawyer: Amped-up protection on the cards for recombinant DNA products

By Greg Chambers

Australian patent authorities continue to wrestle with the treatment of gene-related inventions. A new ruling may extend the life of patents covering medicines made with recombinant DNA technology

The deputy president of the Administrative Appeals Tribunal of Australia (AAT) has overturned a decision from the commissioner of patents to find that the term of a patent with Swiss-style claims can be extended when the claims cover the production of a pharmaceutical substance involving recombinant DNA technology (AbbVie Biotechnology Limited v Commissioner of Patents [2016] AATA 682,...

Issue 86

Take up a trial to IAM. Your three-week free trial would include:

  • Extensive access to the IAM site
  • The editor's weekly review by email
  • Free magazine issue delivered direct to you
Trial now Login

Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 86